Effects of INNO-406 in an in vivo CNS Ph⁺ leukemia model. (A) Brains taken at day 16 from untreated, imatinib mesylate–treated or INNO-406–treated mice that had received 5 × 10⁴ Ba/F3/wt bcr-abl^GFP cells. The data shown are representative of 3 independent experiments. (B) The body weights of mice that had received 5 × 10⁴ Ba/F3/wt bcr-abl^GFP cells and that were then not treated (black) or treated with imatinib mesylate (green, 400 mg/kg per day) or INNO-406 (yellow, 6 mg/kg per day; blue, 20 mg/kg per day; red, 60 mg/kg per day; pink, 120 mg/kg per day). BALB/cA Jcl-nu mice (C) and NOD/SCID (D) mice were inoculated into the right cerebral ventricle with 5 × 10⁴ BaF3/wt bcr-abl^GFP cells or 1 × 10⁶ K562^GFP cells, respectively, on day 0. Mice were given vehicle (black), imatinib mesylate (yellow, 120 mg/kg per day), or INNO-406 (light blue, 6 mg/kg per day; red, 20 mg/kg per day; pink, 60 mg/kg per day; dark blue, 120 mg/kg per day) for 14 consecutive days from day 5. *P < .05; **P < .01.